Cellectis (NASDAQ:CLLS) Downgraded by StockNews.com to “Hold”

StockNews.com cut shares of Cellectis (NASDAQ:CLLS) from a buy rating to a hold rating in a report released on Wednesday morning.

Cellectis Stock Up 3.1 %

CLLS opened at $1.31 on Wednesday. The business’s fifty day simple moving average is $1.48 and its 200 day simple moving average is $1.79. Cellectis has a 52 week low of $1.14 and a 52 week high of $3.38. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48. The stock has a market cap of $72.82 million, a PE ratio of -1.01 and a beta of 3.27.

Cellectis (NASDAQ:CLLS) last announced its quarterly earnings data on Thursday, March 13th. The biotechnology company reported ($0.16) EPS for the quarter, missing the consensus estimate of $0.06 by ($0.22). The firm had revenue of $33.22 million for the quarter, compared to the consensus estimate of $5.90 million. Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. As a group, research analysts expect that Cellectis will post -0.46 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Cellectis

Institutional investors and hedge funds have recently made changes to their positions in the business. Millennium Management LLC purchased a new stake in Cellectis during the fourth quarter valued at about $962,000. B Group Inc. bought a new stake in shares of Cellectis in the 4th quarter valued at about $5,547,000. Finally, Wells Fargo & Company MN boosted its holdings in Cellectis by 103.4% during the 4th quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 12,500 shares during the period. Institutional investors own 63.90% of the company’s stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.